Li 2017b.

Methods	Study design: Randomised clinical trial Study duration: February 2014 to February 2017 Duration of follow‐up: 1 year Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology Exclusion criteria: Liver function of Child‐Pugh Class C; history of gastrointestinal bleeding within 3 months; with extrahepatic metastasis; abnormal haematopoietic function; serious infection; inadequate lung, renal, and cardiac function Age (mean ± SD): TACE + MWA: 54.37 ± 12.94 years; TACE alone: 54.68 ± 12.1 3 years Male (n/total): TACE + MWA: 26/36; TACE alone: 27/36 Tumour diameter (mean ± SD, range): TACE + MWA: 3. 74 ± 1. 10 cm, 1.12‐7.45 cm; TACE: 3.26 ± 1.31 cm, 1.30‐7.39 cm. Child‐Pugh Class (patients): Class A: TACE + MWA: 28; TACE: 29 Class B: TACE + MWA: 8; TACE: 7
Interventions	TACE + MWA group (n = 36): TACE: Chemotherapeutic drugs: oxaliplatin 10 mL MWA: CT‐guided MWA TACE group (n = 36): Chemotherapeutic drugs: oxaliplatin 10 mL
Outcomes	Tumour response: Classified as complete necrosis and progression; measured at 6 months after treatment Adverse events Survival rate Recurrence rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.